enquiry@dsij.in |+91 9240904920
SENSEX-570.59
71,909.7-0.79%

Wipro AI services expansion and margin recovery support growth despite near-term weakness

Wipro Ltd.

Broker Recommendation:

BUY

Broker: Deven Choksey Research

17 Jul 2026

Sector: IT

Original PDF
Reco. Price

₹174

CMP

₹159.5

Target

₹205

Upside

17.82%

Investment View and AI-Led Growth Strategy

In its July 17, 2026 result update, Deven Choksey Research retained its BUY view on Wipro Ltd. The broker believes that AI-led service expansion, geographic diversification, margin normalisation and capital returns can support shareholder value despite subdued near-term growth.

The broker believes the market may be treating AI as a threat to Wipro's legacy operations, whereas management sees incremental spending opportunities in new categories including agent orchestration, sovereign AI, model operations and AI governance. Wipro's AI engagements are increasingly platform-led through WINGS, WEGA and the Reimagine AI portfolio. Consulting and platform work commands premium pricing and is expected to be margin accretive.

Q1 FY27 Financial Performance

Wipro's Q1 FY27 IT Services revenue was USD 2.61 billion, down 1.2 per cent quarter on quarter in constant currency and up 0.9 per cent year on year in constant currency, within guidance. Reported revenue rose 1.0 per cent quarter on quarter and 10.6 per cent year on year to Rs 2,44,786 million, including two months of revenue from the Bind acquisition.

Metric Q1 FY27 Change
EBITDA Rs 46,332 million Down 5.6% QoQ
EBITDA margin 18.9% Down 133 bps QoQ
IT Services EBIT margin 16.0% Down 130 bps QoQ
PAT after minority interest Rs 33,520 million Up 0.6% YoY; down 4.3% QoQ
Diluted EPS Rs 3.20 —

The decline in margins reflected annual wage hikes, large-deal transition costs and AI investments.

Geographic and Vertical Performance

APMEA, up 13.5 per cent year on year in constant currency, and Europe, up 6.0 per cent, outperformed and continued to gain revenue mix. Technology and Communications led vertical growth at 10.8 per cent year on year, followed by BFSI at 2.6 per cent and Consumer at 1.9 per cent.

Americas 2 remained weak because of delayed deal ramps and softer discretionary spending. Healthcare and EMR also remained under pressure from US payer and provider budget constraints, and management gave no clear recovery timeline. Management expects Americas BFSI deal ramps and Europe EMR wins to begin supporting sequential improvement from Q3 FY27.

Large_Rhino.webp

Building Wealth Through Established Businesses

Large-cap companies often form the foundation of a resilient portfolio. DSIJ's Large Rhino focuses on fundamentally strong businesses selected through detailed research for long-term investors.

Bookings and Revenue Outlook

Total bookings were USD 3.37 billion, down 32.2 per cent year on year against a high Q1 FY26 base containing mega-deal closures. However, large-deal TCV rose 12.9 per cent quarter on quarter to USD 1.63 billion across 13 deals. Management said some closures moved to Q2 FY27 and described the pipeline as healthy.

Q2 FY27 IT Services revenue guidance is USD 2.57 billion to USD 2.63 billion, implying constant-currency growth of minus 1.5 per cent to plus 0.5 per cent.

Margin Outlook and Capital Returns

Management reiterated its 17.0 per cent to 17.5 per cent IT Services margin aspiration, supported by utilisation improvement, organisational efficiencies and cost optimisation. Utilisation was 83.6 per cent and attrition was stable at 13.9 per cent.

Headcount reached 243,044 due to Bind, although organic headcount declined through AI-driven productivity. Operating cash flow was 98 per cent of net income and free cash flow conversion was 88.2 per cent. Wipro declared an interim dividend of Rs 2 per share and returned more than USD 3 billion to shareholders over the past year.

Forecasts and Valuation

Deven Choksey forecasts revenue, EBIT and PAT CAGRs of 3.2 per cent, 6.7 per cent and 4.4 per cent, respectively, over FY26 to FY28. The broker values Wipro at 15 times FY28E EPS of Rs 13.7, supporting its Rs 205 target price.

Key Risks

  • Further deterioration in Americas 2.
  • Delayed recovery in Healthcare and EMR.
  • Slower-than-expected margin recovery if AI investment costs exceed revenue conversion.
  • Weak booking conversion if Q2 TCV does not recover above USD 3.5 billion.
  • Top-10 client concentration of 23.6 per cent of revenue.
Download Original Research Report

Disclaimer: This is a summary of a research report published by the broker/research house identified above. The views, recommendations, target prices and estimates are those of the respective broker and do not represent DSIJ investment advice. The summary may be AI-assisted, hence please refer to the original report for complete details, disclosures and risks.